Virtual Library

Start Your Search

Akane Sekiguchi



Author of

  • +

    EP1.12 - Small Cell Lung Cancer/NET (ID 202)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.12-36 - Treatment Outcomes and Risk Factors of Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy (Now Available) (ID 442)

      08:00 - 18:00  |  Author(s): Akane Sekiguchi

      • Abstract
      • Slides

      Background

      The aim of this study was to report clinical outcomes and prognostic factors in limited- stage small cell lung cancer (LD-SCLC) patients treated with chemoradiotherapy (CRT).

      Method

      Data on 107 LD-SCLC patients who received CRT between September 2000 and March 2017 were analyzed retrospectively. The median age of the patients was 66 years (range 42–85 years); 79 (73.8%) patients were male and 28 (26.2%) were female. Seventy-four (69.2%) patients received concurrent CRT (CCRT) with 45 Gy in 30 twice-daily fractions (n=52) or with 54–60 Gy in 27–30 once-daily fractions (n=22). The other 33 patients received sequential CRT (SCRT) with 54–60 Gy in 27–30 once-daily fractions. Prophylactic cranial irradiation was administered to 35 (32.7%) patients. Cisplatin/etoposide or carboplatin/etoposide were mainly selected as chemotherapy regimens. Survival rates were estimated using the Kaplan-Meier method, and univariate and multivariate analysis was performed using the log-rank test and Cox proportional hazard model, respectively.

      Result

      Median follow-up duration was for 28.6 months (range 1.6–147.2 months). Three-year overall survival, progression-free survival and cause-specific survival rates were 51.1%, 38.8% and 51.5%, respectively.

      On univariate analysis metastatic lymph node status (N0 vs N≥1) and timing of CRT (CCRT vs SCRT) were detected as significant prognostic factors for overall survival (3-year overall survival: 100% vs 48.2%, p=0.02; and 56.6% vs 37.7%, p=0.04, respectively). On multivariate analysis, however, these factors did not reach statistical significance.

      Conclusion

      Treatment outcomes in LD-SCLC patients suggested metastatic lymph node status and timing of CRT as prognostic factors for overall survival.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.